Ads
related to: Acute Myeloid Leukemia and Stem Cells- Mechanism Of Action
Learn How To Treat Patients
With Ph+ CML-CP Today.
- Treatment Option
Visit The Physician Website To
Learn More About This Treatment.
- Efficacy Information
Physicians, See How This Treatment
May Help Your Patients Today.
- View Patient Profiles
Patients Experience Treatment
Intolerance & Suboptimal Responses
- $0 Co-Pay Information
Patients With Private Insurance
Could Save On Their Prescription.
- Unmet Needs In CML
Are Your Patients Experiencing
Intolerance? Learn About Treatment.
- Mechanism Of Action
Search results
AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell...
Nature· 3 days agoT cells are important for the control of acute myeloid leukemia (AML), a common and often deadly malignancy. We observed that some AML ...
Deerfield Management and Deerfield Foundation Announce Second Annual AML Summit and Recipients of...
The Pilot News· 6 days agoDeerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second ...
bluebird bio reports first commercial gene therapy use By Investing.com
Investing.com· 6 days agoThis development marks a major step in making the treatment accessible to patients with a history of...
Myelofibrosis: A Rare Malignancy Attracting More and More Attention
MedPage Today· 2 weeks agoMyelofibrosis remains a rare disease, even though recent attention to the condition might suggest...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class PRAME-targeted...
Newswise· 2 weeks agoMD Anderson and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) appli
Vor Bio appoints new board member with oncology expertise By Investing.com
Investing.com· 1 week agoVor Bio (NASDAQ:VOR), a biotechnology firm specializing in cell and genome engineering, announced...
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Digital Journal· 4 days agoHeavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for
